+1 - Solvay

More documents

Recommendations

Info

5200 4680 Activities Group sales 2007 = EUR 9 572 million 4160 3640 3120 2600 2080 1560 1040 520 0 600 2 601 2 591 2 270 2 998 3 031 2 785 3 950 3 800 3 507 Pharmaceuticals Chemicals Plastics Group REBIT 2007 = EUR 1 192 million [Including 540 “Corporate & Business Support”: EUR -51 million] 480 420 360 300 240 180 120 60 0 302 451 457 285 315 345 389 409 Pharmaceuticals Chemicals Plastics Group employees at January 1, 2008: 28 340 people A global presence Group sales 2007 = EUR 9 572 million 32 % 9 % 3 % 56 % Customer markets Group sales 2007 = EUR 9 572 million � Europe 51 % European Union (27) 5 % Other European countries � The Americas 24 % Nafta 8 % Mercosur � Asia-Pacific � Rest of world Human health 29 % Construction and architecture 13 % Automobile industry 12 % Chemical industry 9 % Glass industry 6 % Water and the environment 5 % Electricity and electronics 4 % 6 033 2 189 441 54 Nafta 26 % Mercosul 8 % 20 064 � 2005 � 2006 � 2007 � 2005 � 2006 � 2007 Les Amériques 34 % Sales by Sector in 2007 41 % 35 % 28 % 32 % 27 % REBIT* by Sector in 2007 *Excluding “Corporate & Business Support” : EUR-51 million 8 977 Group employees at January 1, 2008: 28 340 people 1 789 8 396 37 % Employees by Sector in 2007 9 178 � Europe 18 923 European Union (27) 1 141 Other European countries � The Americas Reste 4 531 du Nafta monde 3 1 % 502 Mercosur � Asia-Pacific � 1 531 Rest of world Europe 55 % � Pharmaceuticals � Chemicals � Plastics � Pharmaceuticals � Chemicals � Plastics � Pharmaceuticals � Chemicals � Plastics � Corporate Union Européenne (25) 50 % Autres pays européens 5 % Paper Detergents, cleaning and 4 % Asie hygiene products Pacifique 3 % Packaging 8 % 3 % Consumer goods 2 % Human and animal food processing 1 % Other industries 9 %
February Perfluoropolyether Solvay Solexis expands perfluoropolyether (PFPE) production capacity at Spinetta Marengo (Italy). June Printed memories Solvay Solexis and Thin Film Electronics (Norway) sign an agreement to develop materials for printed memories. July Hydrogen peroxide Solvay and Dow announce they are building a hydrogen peroxide plant in Thailand to feed propylene oxide production. November Fenofibrate March - September SolVin New clinical data show that Solvay’s fenofibrate reduces the risks from the main causes of vision loss in type 2 diabetes patients. SolVin announces the expansion of its polyvinylidene chloride (PVDC) latex capacity at its world-class site at Tavaux (France), with a new production unit to be operational by mid-2009. August Bifeprunox Solvay Pharmaceuticals and Wyeth Pharmaceuticals receive a “not approvable” letter from the Food and Drug Administration (FDA) for bifeprunox, an investigational treatment for schizophrenia. China The new peracetic acid (PAA) plant at Suzhou (China) becomes fully operational. October Caprolactones Solvay signs agreement to sell the Group’s entire Caprolactones business to Sweden’s Perstorp Group. Pipelife April Pipelife June Pipelife begins production of a complete range of plastic pipe systems at its new Russian plant. Pipelife reinforces its product portfolio by acquiring speciality pipes & fittings manufacturer Quality Plastics (Ireland). May Inergy Automotive Systems Inergy Automotive Systems announces new fuel systems activities in China, India and Russia. Soda ash Solvay Sodi decides to expand its soda ash production capacity at Devnya (Bulgaria) to keep up with customer growth. August Plextronics Solvay extends its printable electronics development platform by investing in Plextronics (USA). September EPICEROL ® Solvay announces it is building a world-class epichlorohydrin production plant in Thailand, to be ready by the end of 2009. October SOLVIVA 2007 Highlights June Solvay unveils a series of innovative products at the K2007 International Plastics Trade Fair in Düsseldorf (Germany), including the SOLVIVA range for implantable medical devices. November SEP Russia Solvay agrees to sell its Solvay Engineered Polymers subsidiary (USA) to Basell, a major producer of polypropylene compounds, for which, unlike Solvay, this acquisition is a natural fit. Solvay, SolVin and Sibur sign a joint venture agreement to build the first world class vinyls production plant in Russia. October China Solvay Solexis confirms its intention to expand its specialty polymers activities at the Changshu site (China). October Fluor chemicals business Solvay takes steps to restore the competitiveness of its fluor chemicals business, focusing on high value added specialties and reducing its exposure to the fluorinated gases market, which is under attack from Chinese competition. December Bioethanol Solvay Indupa is to produce bioethanol-based vinyl in Brazil and is planning electricity power generation at its Argentine site. Fenofibrate Filing of a registration application in the USA for SLV348, a new generation fenofibrate developed with Abbott. Solvay Global Annual Report 2007 Highlights 1
Page 1 and 2: Ready for tomorrow Growth, Competit
Page 3: Key figures - Solvay Group Financia
Page 7 and 8: Strategy of sustainable and profita
Page 9 and 10: Solvay is an independent, ethical a
Page 11 and 12: Resources area, beginning with the
Page 13 and 14: Chemicals Sales: EUR 3.0 billion -
Page 15 and 16: Record operating result for Solvay
Page 17 and 18: EUR million 2006 2007 2007/2006 Gro
Page 19 and 20: Capital expenditures and Research a
Page 21 and 22: Current profit before taxes amounte
Page 23 and 24: Joachim Adam Scientific expert Phar
Page 25 and 26: Products Our present offering inclu
Page 27 and 28: Gerda Greeve Microbiological analys
Page 29 and 30: Suzanne Hattink Microbiological ana
Page 31 and 32: Wolgang Kalbe Technical Expert Adri
Page 33 and 34: Research and Development pipeline P
Page 35 and 36: On the path of growth Paolo Bartoli
Page 37 and 38: Energy All our extension projects i
Page 39 and 40: expansions were successfully brough
Page 41 and 42: New Calcium Chloride production pla
Page 43 and 44: The “Organic” cluster: Molecula
Page 45 and 46: Jean-Jacques Lootens Coating operat
Page 47 and 48: PVC In a context of high oil prices
Page 49 and 50: SOLVERA ® and FLUORLINK ® brand n
Page 51 and 52: Despite considerable capacity incre
Page 53 and 54: How do the Plastics Sector’s acti
Page 55 and 56:
New Business Development Thierry De
Page 57 and 58:
organized in November 2007 - each d
Page 59 and 60:
Since 2004, Solvay has been working
Page 61 and 62:
The most important development in t
Page 63 and 64:
The new river port at the Rheinberg
Page 65 and 66:
During the June 2006 strategic revi
Page 67 and 68:
They are also the “architects”
Page 69 and 70:
Financial Statements The following
Page 71 and 72:
Goodwill EUR Million Notes 2006 200
Page 73 and 74:
Fair value differences These record
Page 75 and 76:
• IFRIC 14 IAS 19 The Limit on a
Page 77 and 78:
• the assets will generate future
Page 79 and 80:
Notes to the financial statements T
Page 81 and 82:
(2) Financial data by region Group
Page 83 and 84:
The EUR 123 million of asset impair
Page 85 and 86:
(12b) Deferred taxes on the balance
Page 87 and 88:
(19) Acquisition / sale of assets a
Page 89 and 90:
The 3-year vesting period is follow
Page 91 and 92:
(23) Goodwill EUR Million Total Gro
Page 93 and 94:
Finance leases EUR Million Land and
Page 95 and 96:
The table below shows the evolution
Page 97 and 98:
The amounts recorded in the balance
Page 99 and 100:
Actuarial assumptions used in deter
Page 101 and 102:
The amount of the provisions reflec
Page 103 and 104:
Cash and cash equivalents Cash and
Page 105 and 106:
Managing the transactional exchange
Page 107 and 108:
Financial instruments IAS 39 define
Page 109 and 110:
(32) Contingent liabilities EUR Mil
Page 111 and 112:
1. Market & Growth - Strategic Risk
Page 113 and 114:
To manage legal risk Solvay maintai
Page 115 and 116:
• Product Development Risk is Sol
Page 117 and 118:
2007 Consolidation Scope The Group
Page 119 and 120:
List of fully consolidated Group co
Page 121 and 122:
Solvay Healthcare Ltd, Southampton
Page 123 and 124:
List of proportionately consolidate
Page 125 and 126:
ARGENTINA Inergy Automotive Systems
Page 127 and 128:
Income statement of Solvay S.A. (su
Page 129 and 130:
Additional comment The preparation
Page 131 and 132:
Report on the application of the Co
Page 133 and 134:
Introduction This report presents t
Page 135 and 136:
June 2005 for a three-year period b
Page 137 and 138:
certainty the shareholders authoriz
Page 139 and 140:
Year of birth Year of 1st appointme
Page 141 and 142:
which could potentially affect the
Page 143 and 144:
attendance fees for participating i
Page 145 and 146:
They are not signed, but the Chairm
Page 147 and 148:
enewal of their terms of office, on
Page 149 and 150:
The Solvay share compared with the
Page 151 and 152:
ANNEXE 2 COMPENSATION POLICY FOR GE
Page 153 and 154:
“ … I have always sought to ser
Page 155 and 156:
1. Mr. Aloïs Michielsen (B) 2 0 0
Page 157 and 158:
Executive Committee and General Man
Page 159 and 160:
ABAF: Belgian Financial Analysts As
Page 161 and 162:
Shareholders’ Diary - Tuesday May
show all

+1 - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?